LONN.SW in “Drug Manufacturing De-Risks From China”
Lonza Group AG
Lonza is a leading Western biologics manufacturer positioned to capture programs moved away from Chinese suppliers.
LONN.SW impact map — “Drug Manufacturing De-Risks From China”
How this story travels from the headline to LONN.SW’s own business — positive, negative or mixed, direct or indirect, the mechanism, and how strong the exposure is.
Loading LONN.SW impact map…
Price history, marked with story events
Aug 31, 2026 – Oct 19, 2026 · 36 sessions
Prices updated during market hours · refreshed about every 30 minutes while the market is open · delayed data, not for trading decisions
Numbered markers tie price moves to earnings, trial or study results, management comments and analyst or demand data. Loading events…
Full story
Drug Manufacturing De-Risks From China
Western drugmakers are paying for non-Chinese capacity before procurement restrictions become binding.
BULL side — Lonza is a leading Western biologics manufacturer positioned to capture programs moved away from Chinese suppliers.
Read the full Drug Manufacturing De-Risks From China storyBull side
2 stories- Viewing
LONN.SW in “Drug Manufacturing De-Risks From China”
FadingExposure: not rated yetWestern drugmakers are paying for non-Chinese capacity before procurement restrictions become binding.
Lonza is a leading Western biologics manufacturer positioned to capture programs moved away from Chinese suppliers.
- The Patent Cliff Sparks a Biotech Land Grab
LONN.SW in “The Patent Cliff Sparks a Biotech Land Grab”
FadingExposure: not rated yetLarge drugmakers facing revenue holes must buy scarce pipelines, turning clinical validation into strategic currency.
Lonza benefits as acquired biologics and advanced therapies require complex development and outsourced manufacturing capacity.
Bear side
0 storiesNo bear-side stories for LONN.SW yet.